• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Potential significance of TRPC3/6 and CNP as novel therapeutic targets of pulmonary arterial hypertension

Research Project

Project/Area Number 18K08034
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 53020:Cardiology-related
Research InstitutionKyoto University

Principal Investigator

Hideyuki Kinoshita  京都大学, 医学研究科, 特定准教授 (30467477)

Co-Investigator(Kenkyū-buntansha) 桑原 宏一郎  信州大学, 学術研究院医学系, 教授 (30402887)
中川 靖章  京都大学, 医学研究科, 助教 (70452357)
Project Period (FY) 2018-04-01 – 2021-03-31
Project Status Completed (Fiscal Year 2020)
Budget Amount *help
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2020: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Keywords肺動脈性肺高血圧症 / 病的心臓リモデリング / 受容体活性化型Caチャネル / ナトリウム利尿ペプチド / 心不全 / 右室肥大 / 肺動脈性肺高血圧 / Caチャネル / 肺高血圧症 / TRPC / CNP
Outline of Final Research Achievements

Pulmonary hypertension (PH) is a disease with a poor prognosis, and the further therapeutic agent is required. We analyzed the effect of classic transient receptor potental channel 3/6 (TRPC3/6), and C-type natriuretic peptide (CNP), one of natriuretic peptide family in the progression of pulmonary hypertension.
TRPC channels inhibitor improved pulmonary hypertension on PH animal models. And also, we analyzed the CNP plays a protective role in the development of PH via endothelial GC-B through inhibiting endothelin-1 and inflammatory signals involvement. These data suggest that inhibition pf TRPC3/6 and CNP could be the novel therapeutic agent for PH.

Academic Significance and Societal Importance of the Research Achievements

難治性疾患である肺高血圧症の発症・進展メカニズムの探索として、従来あまり指摘されていなかった、受容体刺激により活性化されるCaチャンネルであるTRPC3/6や、ナトリウム利尿ペプチドの一種であるCNPの肺高血圧の病態における関与や、そのメカニズムを明かとした。さらに、上記けいろを標的とした治療が肺高血圧症の発症・進展を抑制する可能性を明らかとし、今後の新規治療薬の開発の可能性がある研究結果であったと考える。

Report

(4 results)
  • 2020 Annual Research Report   Final Research Report ( PDF )
  • 2019 Research-status Report
  • 2018 Research-status Report
  • Research Products

    (5 results)

All 2020 2019

All Presentation (5 results) (of which Int'l Joint Research: 1 results,  Invited: 2 results)

  • [Presentation] Endothelial CNP-GC-B system plays a protective role in the development of pulmonary hypertension.2020

    • Author(s)
      Hiromu Yanagisawa, Yasuaki Nakagawa, Kenji Moriuchi, Hideaki Inazumi, Hideyuki Kinoshita, Toshio Nishikimi, Miku Oya, Kazuwa Nakao, Koichiro Kuwahara, Takeshi Kimura.
    • Organizer
      第 4 回日本循環器学会基礎研究フォーラム(BCVR)
    • Related Report
      2020 Annual Research Report
  • [Presentation] 肺疾患を 合併した肺動脈性肺高血圧症に対するマシテンタンの効果2020

    • Author(s)
      嶋本光兵,木下秀之,柳澤洋,森内健史,稲住英明,中川靖章,桑原宏一郎,木村剛
    • Organizer
      第 5 回日本肺高血圧・肺循環学会学術集会
    • Related Report
      2020 Annual Research Report
  • [Presentation] 呼吸器疾患を合併した肺動脈性肺高血圧症の治療を考える2020

    • Author(s)
      木下秀之
    • Organizer
      第 60 回日本呼吸器学会学術講演会
    • Related Report
      2020 Annual Research Report
    • Invited
  • [Presentation] 膠原病に伴う肺動脈性肺高血圧症の診断とマネジメントにおける問題点を考える2020

    • Author(s)
      木下秀之
    • Organizer
      第 48 回日本臨床免疫学会総会
    • Related Report
      2020 Annual Research Report
    • Invited
  • [Presentation] Macitentan for the Treatment of Pulmonary Arterial Hypertnsion with Lung Disease.2019

    • Author(s)
      Hideyuki Kinoshita, Hiromu Yanagisawa, Kenji Moriuchi, Hideaki Inazumi, Yasuaki Nakagawa, Koichiro Kuwahara, Takeshi Kimura
    • Organizer
      The 16th International Conference of Endothelin
    • Related Report
      2019 Research-status Report
    • Int'l Joint Research

URL: 

Published: 2018-04-23   Modified: 2022-01-27  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi